Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant camrelizumab plus albumin-bound paclitaxel in resectable stage II/III NSCLC
ChiCTR2200058819Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- May 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and paclitaxel in non-small cell lung cancer (NSCLC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Major pathological response. Planned start May 2022; status: not yet recruiting.
02
Drugs
camrelizumabpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200058819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058819.